Feng Zhang
Pioneer of CRISPR-Cas9 genome editing in human cells, the tool behind cancer dependency screens and edited cell therapies.
Adapted CRISPR-Cas9 for mammalian genome editing (2013) and discovered Cas12/Cas13 systems; his tools underpin genome-wide screens and next-generation engineered cell therapies.
| Title | Journal | Year |
|---|---|---|
| Multiplex genome engineering using CRISPR/Cas systems | Science | 2013 |
Pages like this
not linked directly; found by shared links- PersonFrancisca Vazquez
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
- PersonTodd R. Golub
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
- IdeaAn open atlas of collateral sensitivity for every approved targeted drug
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
- CompanyCaribou Biosciences
Shares Allogeneic (off-the-shelf) cell therapy, CRISPR functional genomics.
- IdeaAttack the backup copy when a tumour has lost the original gene
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
- IdeaAn open model of every cancer cell state, built from perturbation atlases
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
- IdeaAn open foundation model of the cancer cell trained on perturbation data
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
- Key paperDefining a Cancer Dependency Map: which genes each cancer cell line cannot live without
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.